Prioritizing Radiation and Targeted Systemic Therapies in Patients with Resected Brain Metastases from Lung Cancer Primaries with Targetable Mutations: A Report from a Multi-Site Single Institution

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 16

PMID 39409890

Authors

Yen-Ruh Wuu

Mostafa Kokabee

Bin Gui

Simon Lee

Jacob Stone

Jessie Karten

Randy S DAmico

Morana Vojnic

A Gabriella Wernicke

Affiliations

Soon will be listed here.

Abstract

: Brain metastases (BrMs) are a common complication of non-small cell lung cancer (NSCLC), present in up to 50% of patients. While the treatment of BrMs requires a multidisciplinary approach with surgery, radiotherapy (RT), and systemic therapy, the advances in molecular sequencing have improved outcomes in patients with targetable mutations. With a push towards the molecular characterization of cancers, we evaluated the outcomes by treatment modality at our institution with respect to prioritizing RT and targeted therapies. : We identified the patients with NSCLC BrMs treated with surgical resection. The primary endpoints were in-brain freedom from progression (FFP) and overall survival (OS). The secondary endpoint included index lesion recurrence. The tumor molecular profiles were reviewed. The outcomes were evaluated by treatment modality: surgery followed by adjuvant RT and/or adjuvant systemic therapy. : In total, 155/272 (57%) patients who received adjuvant therapy with adequate follow-up were included in this analysis. The patients treated with combination therapy vs. monotherapy had a median FFP time of 10.72 months vs. 5.38 months, respectively ( = 0.072). The patients of Hispanic/Latino vs. non-Hispanic/Latino descent had a statistically significant worse OS of 12.75 months vs. 53.15 months, respectively ( = 0.015). The patients who received multimodality therapy had a trend towards a reduction in index lesion recurrences (χ test, = 0.063) with a statistically significant improvement in the patients receiving immunotherapy (χ test, = 0.0018). : We found that systemic therapy combined with RT may have an increasing role in delaying the time to progression; however, there was no statistically significant relationship between OS and treatment modality.

References

Myall N, Yu H, Soltys S, Wakelee H, Pollom E . Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. Neurooncol Adv. 2021; 3(Suppl 5):v52-v62. PMC: 8633733. DOI: 10.1093/noajnl/vdab106. View

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483-91. DOI: 10.1001/jama.295.21.2483. View

Kuan A, Chiang C, Wu H, Yang H, Chen C, Lin C . Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses. J Neurooncol. 2023; 164(3):729-739. DOI: 10.1007/s11060-023-04452-x. View

Chiou G, Chiang C, Yang H, Shen C, Wu H, Chen Y . Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases. J Neurosurg. 2021; 137(2):563-570. DOI: 10.3171/2021.9.JNS211373. View

Schouten L, Rutten J, Huveneers H, Twijnstra A . Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002; 94(10):2698-705. DOI: 10.1002/cncr.10541. View

Andrews L, Thornton Z, Saleh R, Dawson S, Short S, Daly R . Genomic landscape and actionable mutations of brain metastases derived from non-small cell lung cancer: A systematic review. Neurooncol Adv. 2023; 5(1):vdad145. PMC: 10734675. DOI: 10.1093/noajnl/vdad145. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View

Singh K, Saxena S, Khosla A, McDermott M, Kotecha R, Ahluwalia M . Update on the Management of Brain Metastasis. Neurotherapeutics. 2022; 19(6):1772-1781. PMC: 9723062. DOI: 10.1007/s13311-022-01312-w. View

10.

Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G . Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open. 2018; 3(1):e000262. PMC: 5786916. DOI: 10.1136/esmoopen-2017-000262. View

11.

Dee E, Swami N, Kazzi B, Lapen K, Franco I, Jain B . Disparities in Stage at Presentation Among Hispanic and Latinx Patients With Non-Small-Cell Lung Cancer in the United States. JCO Oncol Pract. 2024; 20(4):525-537. DOI: 10.1200/OP.23.00474. View

12.

Almquist D, Ernani V . The Road Less Traveled: A Guide to Metastatic -Rearranged Non-Small-Cell Lung Cancer. JCO Oncol Pract. 2020; 17(1):7-14. DOI: 10.1200/OP.20.00819. View

13.

Vogelbaum M, Brown P, Messersmith H, Brastianos P, Burri S, Cahill D . Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2021; 40(5):492-516. DOI: 10.1200/JCO.21.02314. View

14.

Amouzegar A, Haig S, Kahn A, Tawbi H, Jones J, Goldberg S . Navigating the Complexities of Brain Metastases Management. Am Soc Clin Oncol Educ Book. 2024; 44(3):e433694. DOI: 10.1200/EDBK_433694. View

15.

Escobedo L, Cervantes L, Havranek E . Barriers in Healthcare for Latinx Patients with Limited English Proficiency-a Narrative Review. J Gen Intern Med. 2023; 38(5):1264-1271. PMC: 9888733. DOI: 10.1007/s11606-022-07995-3. View

16.

Chen Y, Wei J, Cai J, Liu A . Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis. BMC Cancer. 2019; 19(1):793. PMC: 6688250. DOI: 10.1186/s12885-019-6005-6. View

17.

Gu W, Liu P, Tang J, Lai J, Wang S, Zhang J . The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs. Front Oncol. 2024; 13:1288468. PMC: 10875041. DOI: 10.3389/fonc.2023.1288468. View

18.

Kahraman S, Karakaya S, Kaplan M, Sezgin Goksu S, Ozturk A, Isleyen Z . Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases. Sci Rep. 2024; 14(1):5820. PMC: 10925043. DOI: 10.1038/s41598-024-56046-w. View

19.

Thomas N, Myall N, Sun F, Patil T, Mushtaq R, Yu C . Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol. 2021; 17(1):116-129. DOI: 10.1016/j.jtho.2021.08.009. View

20.

Piffko A, Asey B, Duhrsen L, Ristow I, Salamon J, Wikman H . Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer. Front Oncol. 2022; 12:951805. PMC: 9631813. DOI: 10.3389/fonc.2022.951805. View